​

Lexeo Therapeutics (LXEO) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

LXEO Stock Forecast

Lexeo Therapeutics (LXEO) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $19.83, with a high of $30.00 and a low of $13.00. This represents a 103.80% increase from the last price of $9.73.

$5 $10 $15 $20 $25 $30 High: $30 Avg: $19.83 Low: $13 Last Closed Price: $9.73

LXEO Stock Rating

Lexeo Therapeutics stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 5 Strong Sell Sell Hold Buy Strong Buy

LXEO Price Target Upside V Benchmarks

TypeNameUpside
StockLexeo Therapeutics103.80%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts277
Avg Price Target$19.50$19.14$19.14
Last Closing Price$9.73$9.73$9.73
Upside/Downside100.41%96.71%96.71%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 2528---10
Nov, 2536---9
Oct, 2535---8
Sep, 2535---8
Aug, 2535---8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 10, 2025Leland GershellOppenheimer$20.00$9.51110.30%105.55%
Nov 20, 2025Cantor Fitzgerald$19.00$9.09109.02%95.27%
Oct 21, 2025H.C. Wainwright$13.00$9.2241.00%33.61%
Oct 15, 2025Guggenheim$30.00$8.50252.94%208.32%
Oct 07, 2025Chardan Capital$17.00$8.25106.06%74.72%
Oct 07, 2025H.C. Wainwright$15.00$8.2581.82%54.16%
Oct 07, 2025Mani ForooharLeerink Partners$20.00$8.25142.42%105.55%
Jun 12, 2024Brian SkorneyRobert W. Baird$28.00$18.1953.93%187.77%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 10, 2025OppenheimerOutperformOutperformhold
Dec 01, 2025Cantor FitzgeraldOverweightOverweighthold
Nov 20, 2025Cantor FitzgeraldOverweightinitialise
Nov 03, 2025H.C. WainwrightBuyBuyhold
Oct 15, 2025GuggenheimBuyinitialise
Oct 07, 2025H.C. WainwrightBuyBuyhold
Jul 31, 2025OppenheimerOutperforminitialise
Jun 06, 2024H.C. WainwrightBuyinitialise
Mar 12, 2024RBC CapitalOutperformOutperformhold

Financial Forecast

EPS Forecast

$-11 $-9 $-7 $-5 $-3 $-1 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.49$-3.09----
Avg Forecast$-6.66$-3.12$-3.01$-3.12$-3.56$-2.81
High Forecast$-3.95$-3.01$-1.94$-1.78$-3.56$-2.81
Low Forecast$-10.30$-3.29$-4.16$-4.63$-3.56$-2.81
Surprise %-62.61%-0.96%----

Revenue Forecast

$50M $110M $170M $230M $290M $350M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast-$4.50M$1.13M-$57.00M$321.00M
High Forecast-$4.50M$1.13M-$57.00M$321.00M
Low Forecast-$4.50M$1.13M-$57.00M$321.00M
Surprise %------

Net Income Forecast

$-300M $-240M $-180M $-120M $-60M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-66.39M$-98.33M----
Avg Forecast$-189.88M$-86.60M$-104.22M$-89.22M$-94.73M$-74.88M
High Forecast$-105.25M$-80.23M$-51.61M$-47.45M$-94.73M$-74.88M
Low Forecast$-274.51M$-87.64M$-110.72M$-123.49M$-94.73M$-74.88M
Surprise %-65.03%13.55%----

LXEO Forecast FAQ

Is Lexeo Therapeutics stock a buy?

Lexeo Therapeutics stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Lexeo Therapeutics is a favorable investment for most analysts.

What is Lexeo Therapeutics's price target?

Lexeo Therapeutics's price target, set by 5 Wall Street analysts, averages $19.83 over the next 12 months. The price target range spans from $13 at the low end to $30 at the high end, suggesting a potential 103.80% change from the previous closing price of $9.73.

How does Lexeo Therapeutics stock forecast compare to its benchmarks?

Lexeo Therapeutics's stock forecast shows a 103.80% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Lexeo Therapeutics over the past three months?

  • December 2025: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 37.50% Strong Buy, 62.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Lexeo Therapeutics’s EPS forecast?

Lexeo Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.01, marking a -2.59% decrease from the reported $-3.09 in 2024. Estimates for the following years are $-3.12 in 2026, $-3.56 in 2027, and $-2.81 in 2028.

What is Lexeo Therapeutics’s revenue forecast?

Lexeo Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $1.12M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $0, followed by $57M for 2027, and $321M for 2028.

What is Lexeo Therapeutics’s net income forecast?

Lexeo Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-104M, representing an 5.98% increase from the reported $-98.333M in 2024. Projections indicate $-89.223M in 2026, $-94.728M in 2027, and $-74.876M in 2028.